Geron Corporation (Nasdaq: GERN) is a clinical stage pharmaceutical company with a current market cap of just over $300 million. Geron has one drug in its pipeline, a telomerase inhibitor called … [Read more...] about Geron: The Neverending Story
Last week Verastem presented additional Copiktra data at the Leerinks Health Care Conference followed by a Q&A session by analysts. The webcast can be accessed here. In this article, I discuss the … [Read more...] about Can Verastem Shake the DownTrend?
Last fall, Verastem Oncology (NASDAQ: VSTM) received FDA-approval for its first drug, Copiktra, an oral monotherapy for the treatment of relapsed or refractory chronic lymphotic leukemia, small … [Read more...] about Verastem Oncology: Looking for a Port in the Storm
I have recently received many questions on the micro-cap stock Sesen Bio (Nasdaq: SESN). This small company is attempting to make a big name for itself in the area of non-muscle invasive bladder … [Read more...] about Sesen Bio: Are the VISTA Results Up to Par?
Acquisitions in pharmaceutical industry staying at an elevated paceStrong balance sheet even before having any drugs approved for salePromising lentiviral genetic treatment platformSignificant … [Read more...] about Acquisition Targets: Could Bluebird Be In Season?
Lymphoma Patients Want and Need A Better Quality Of Life As a Lymphoma survivor, I can say unequivocally, that TO MUCH TIME is spent in the chemo wing, away from our families. Therefore, as … [Read more...] about (Nasdaq: VSTM) Verastem, Better Quality of Life? A Patients Perspective
Alzheimer disease (AD) is the most common form of dementia. AD is characterized by amyloid plaques and neurofibrillary tangles in the brain, with associated loss of synapses and neurons, … [Read more...] about TAU Me One More Time
Novo Nordisk (NYSE: NVO) is a global healthcare company engaged in diabetes care, obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other … [Read more...] about Is Novo Nordisk Ready For Increased Biosimilar Competition?
Introduction Trevena Inc. (Nasdaq: TRVN) spiked 119% from the $.5 range to $1.19 on January 28th. The catalyst being positive regulatory updates from the FDA Type A meeting minutes. In a nut-shell the … [Read more...] about 2019 Should Be A Good Year For TRVN, But What’s Next?
Leave a comment and click here to sub for MS Equity Analysis and Swing Moves. Introduction You may have recently seen hype about Corbus Pharmaceuticals (Nasdaq: CRBP), … [Read more...] about CRBP – Is Corbus Pharmaceuticals a good buy?